M&As this week: Johnson & Johnson, LivaNova, LGC Limited

23 February 2018 (Last Updated February 23rd, 2018 15:09)

Johnson and Johnson (J&J), through its French affiliate Apsis SAS, has acquired Orthotaxy SAS, a software-enabled surgery technologies developer based in France.

Johnson and Johnson (J&J), through its French affiliate Apsis SAS, has acquired Orthotaxy SAS, a software-enabled surgery technologies developer based in France.

The acquisition will enable J&J to provide innovative digital surgery solutions to its customers.

Based in the US, J&J is engaged in the development, manufacture and sale of healthcare products.

UK-based medical technology company LivaNova has signed an agreement to purchase TandemLife, a medical device company based in the US, for $250m.

The transaction includes an upfront payment of $200m and $50m contingent considerations based on regulatory milestones.

TandemLife offers four temporary medical support devices named TandemLife, ProtekDuo, TandemLung, and TandemHeart, which can be deployed in hospitals for acute cardiac and cardiopulmonary care.

“TandemLife’s support solutions will complement LivaNova’s cardiac surgery offerings and enable the company to expand its footprint in the US and international markets.”

TandemLife’s support solutions will complement LivaNova’s cardiac surgery offerings and enable the company to expand its footprint in the US and international markets.

The transaction is expected to close in the first half of this year.

LGC Limited has completed the acquisition of US-based life sciences and healthcare products provider Lucigen Corporation.

Lucigen will remain the exclusive worldwide distributor of the Epicentre brand products to scientists, as part of the transaction.

Based in the UK, LGC is a life sciences measurement and testing company.

LGC will be able to expand its business in the next-generation sequencing (NGS) and gene-editing markets through the acquisition.